Gapping down
In reaction to disappointing earnings/guidance:
- DAKT -25.8%, MNTA -18.4%, HSBC -6.2%, DDS -4.9%, CYOU -4.2%, AMRI -3.5%, SOHU -3.2%, WAB -3%, MGIC -2.6%, UIHC -2.5%
- CBRL -1.6%, AU -1.3%, PWR -1.2%, CRMT -0.6%
M&A news:
- UL -8.5% (Unilever and Kraft Heinz (KHC) jointly confirm that KHC has amicably agreed to withdraw its proposal for a combination of the two companies )
- UN -8.3%, KHC -5%
Other news:
- TRVN -33.4% (announces its Phase 3 APOLLO-1 and APOLLO-2 pivotal efficacy studies of oliceridine)
- CDTX -32.6% (reports that the Phase 2 RADIANT clinical trial in acute vulvovaginal candidiasi did not show sufficient efficacy to justify further development)
- MNTA -18.9% (receives notice of warning letter from FDA to contracted Glatopa; Approval of the Glatopa 40 mg ANDA will be dependent on resolution of Pfizer (PFE) facility compliance issues)
- DRYS -18.8% (enters into $200 mln stock purchase agreement with Kalani Investments)
- IMMU -3.4% (files a federal lawsuit and a motion seeking injunctive relief against venBio Select Advisor and venBio's four director candidates)
- GMS -3.1% (commences 6 mln common stock offering by its existing stockholders, including certain affiliates of AEA Investors LP)
- ING -1.1% (in sympathy with HSBC earnings)
Analyst comments:
- FCX -3.7% (downgraded to Sell from Hold at Deutsche Bank)
- EIGI -3.2% (downgraded to Underweight from Equal-Weight at Morgan Stanley)
- DKS -1.1% (downgraded to Perform from Outperform at Oppenheimer)
- OHI -0.9% (downgraded to Hold from Buy at Jefferies)
- BLMN -0.8% (downgraded to Neutral from Overweight at JP Morgan)